7ACC2
Based on 11 publication(s) in Google Scholar
7ACC2 is a potent monocarboxylate transporter (MCT) inhibitor with an IC50 of 11 nM for inhibition of [14C]-lactate influx. 7ACC2 is also a potent inhibitor of mitochondrial pyruvate transport. 7ACC2 is an anticancer agent through inhibition of lactate flux.
For research use only. We do not sell to patients.
- Purity: 99.95%
- CAS No.: 1472624-85-3
- Formula: C18H15NO4
- Molecular Weight:309.32
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) 7ACC2
More- Cell. 2021 Jan 21;184(2):370-383.e13. [Abstract]
- Cell Host Microbe. 2026 Feb 11;34(2):245-262.e8. [Abstract]
- Adv Sci (Weinh). 2025 Jul 29:e05436. [Abstract]
- Theranostics. 2019 Jan 30;9(4):1001-1014. [Abstract]
- Redox Biol. 2024 Aug:74:103209. [Abstract]
- EBioMedicine. 2023 Feb:88:104444. [Abstract]
- J Immunother Cancer. 2025 Dec 3;13(12):e013733. [Abstract]
- Clin Transl Med. 2021 Jun;11(6):e467. [Abstract]
- OncoImmunology. 2022 Dec 22;12(1):2160558. [Abstract]
- ACS Biomater Sci Eng. 2026 Feb 9;12(2):1018-1031. [Abstract]
- bioRxiv. 2026 Jun 18.
-
WB
Biological Activity
IC50: 11 nM (Monocarboxylate transporter)[1]
Mitochondrial pyruvate transport[2]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SiHa | EC50 |
0.22 μM
Compound: 19
|
Cytotoxicity against human SiHa cells in lactate-containing medium after 72 hrs by MTT assay
Cytotoxicity against human SiHa cells in lactate-containing medium after 72 hrs by MTT assay
|
[PMID: 24095010] |
| SiHa | IC50 |
0.059 μM
Compound: 19
|
Inhibition of MCT4-mediated [14C]-lactate uptake in human SiHa cells in lactate-containing medium assessed as remaining lactate concentration in culture medium after 24 hrs by liquid scintillation counting
Inhibition of MCT4-mediated [14C]-lactate uptake in human SiHa cells in lactate-containing medium assessed as remaining lactate concentration in culture medium after 24 hrs by liquid scintillation counting
|
[PMID: 24095010] |
| SiHa | IC50 |
10 nM
Compound: 19
|
Inhibition of MCT4-mediated [14C]-lactate uptake in human SiHa cells in lactate-containing medium assessed as remaining lactate concentration in culture medium after 12 mins by liquid scintillation counting
Inhibition of MCT4-mediated [14C]-lactate uptake in human SiHa cells in lactate-containing medium assessed as remaining lactate concentration in culture medium after 12 mins by liquid scintillation counting
|
[PMID: 24095010] |
7ACC2 (compound 19; 72 hours) inhibits SiHa cells proliferation in lactate-containing medium with an EC50 of 0.22 μM. In SiHa cells, lactate uptake primarily depends on the high affinity MCT1 transporter[1].
7ACC2 (compound 19) shows an excellent chemical stability in simulated gastric (SGF) and intestinal (SIF) fluids, a good apparent permeability coefficient (Papp) through Caco-2 monolayer and a high metabolic stability on mouse (MLM) and human liver microsomes (HLM) as well as on human hepatocytes[1].
7ACC2 is a potent inhibitor of mitochondrial pyruvate transport which consecutively blocks extracellular lactate uptake by promoting intracellular pyruvate accumulation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
The intraperitoneal administration of 7ACC2 (compound 19; 3 mg/kg) to mice leads to a Cmax of 1246 ng/ml (4 μM) in a very short time (Tmax=10 min) associated with a plasma half-life of 4.5 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:7-week-old female NMRI nude mice with radiotherapy administered[2]
-
Dosage:3 mg/kg
-
Administration:Intraperitoneal administration; daily; for 5 days or 10days
-
Result:A significant increase in tumor growth delay was observed.
Chemical Information
-
CAS No. 1472624-85-3
-
Appearance Solid
-
Molecular Weight 309.32
-
Formula C18H15NO4
-
Color Light yellow to yellow
-
SMILES
CN(C1=CC=C(C=C(C(O)=O)C(O2)=O)C2=C1)CC3=CC=CC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Cell
Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates. [Abstract]2021 Jan 21;184(2):370-383.e13. PMID: 33333023 -
Cell Host Microbe
Enterococcus faecalis-derived lactic acid suppresses macrophage activation to facilitate persistent and polymicrobial wound infections. [Abstract]2026 Feb 11;34(2):245-262.e8. PMID: 41605216 -
Adv Sci (Weinh)
2025 Jul 29:e05436. PMID: 40726407 -
Theranostics
Tumor-secreted dickkopf2 accelerates aerobic glycolysis and promotes angiogenesis in colorectal cancer. [Abstract]2019 Jan 30;9(4):1001-1014. PMID: 30867812 -
Redox Biol
Lactate-induced activation of tumor-associated fibroblasts and IL-8-mediated macrophage recruitment promote lung cancer progression. [Abstract]2024 Aug:74:103209. PMID: 38861833 -
EBioMedicine
F. nucleatum facilitates oral squamous cell carcinoma progression via GLUT1-driven lactate production. [Abstract]2023 Feb:88:104444. PMID: 36709580 -
J Immunother Cancer
2025 Dec 3;13(12):e013733. PMID: 41339107 -
Clin Transl Med
Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. [Abstract]2021 Jun;11(6):e467. PMID: 34185423 -
OncoImmunology
Altered phenotypic and metabolic characteristics of FOXP3+CD3+CD56+ natural killer T (NKT)-like cells in human malignant pleural effusion. [Abstract]2022 Dec 22;12(1):2160558. PMID: 36567801
7ACC2 purchased from MedChemExpress. Usage Cited in: OncoImmunology. 2022 Dec 22;12(1):2160558. [Abstract]
7ACC2 (100 nM; 7 days) decreases H3K18la levels in NKT-like cells.
-
ACS Biomater Sci Eng
Metabolic Radiosensitization by Targeting Lactate Metabolism with Microfluidic Liposomal Nanocarriers. [Abstract]2026 Feb 9;12(2):1018-1031. PMID: 41603671 -
Solvent & Solubility
DMSO : 50 mg/mL (161.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.08 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Draoui N, et al. Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells. Bioorg Med Chem. 2013 Nov 15;21(22):7107-17. [Content Brief]
[2]. Cyril Corbet, et al. Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects. Nat Commun. 2018 Mar 23;9(1):1208. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2329 mL | 16.1645 mL | 32.3290 mL | 80.8224 mL |
| 5 mM | 0.6466 mL | 3.2329 mL | 6.4658 mL | 16.1645 mL | |
| 10 mM | 0.3233 mL | 1.6164 mL | 3.2329 mL | 8.0822 mL | |
| 15 mM | 0.2155 mL | 1.0776 mL | 2.1553 mL | 5.3882 mL | |
| 20 mM | 0.1616 mL | 0.8082 mL | 1.6164 mL | 4.0411 mL | |
| 25 mM | 0.1293 mL | 0.6466 mL | 1.2932 mL | 3.2329 mL | |
| 30 mM | 0.1078 mL | 0.5388 mL | 1.0776 mL | 2.6941 mL | |
| 40 mM | 0.0808 mL | 0.4041 mL | 0.8082 mL | 2.0206 mL | |
| 50 mM | 0.0647 mL | 0.3233 mL | 0.6466 mL | 1.6164 mL | |
| 60 mM | 0.0539 mL | 0.2694 mL | 0.5388 mL | 1.3470 mL | |
| 80 mM | 0.0404 mL | 0.2021 mL | 0.4041 mL | 1.0103 mL | |
| 100 mM | 0.0323 mL | 0.1616 mL | 0.3233 mL | 0.8082 mL |